Cargando…

Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies

Haemoglobinopathies are common monogenic disorders with diverse clinical manifestations, partly attributed to the influence of modifier genes. Recent years have seen enormous growth in the amount of genetic data, instigating the need for ranking methods to identify candidate genes with strong modify...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephanou, Coralea, Tamana, Stella, Minaidou, Anna, Papasavva, Panayiota, Kleanthous, Marina, Kountouris, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912721/
https://www.ncbi.nlm.nih.gov/pubmed/31717530
http://dx.doi.org/10.3390/jcm8111927
_version_ 1783479523826728960
author Stephanou, Coralea
Tamana, Stella
Minaidou, Anna
Papasavva, Panayiota
Kleanthous, Marina
Kountouris, Petros
author_facet Stephanou, Coralea
Tamana, Stella
Minaidou, Anna
Papasavva, Panayiota
Kleanthous, Marina
Kountouris, Petros
author_sort Stephanou, Coralea
collection PubMed
description Haemoglobinopathies are common monogenic disorders with diverse clinical manifestations, partly attributed to the influence of modifier genes. Recent years have seen enormous growth in the amount of genetic data, instigating the need for ranking methods to identify candidate genes with strong modifying effects. Here, we present the first evidence-based gene ranking metric (IthaScore) for haemoglobinopathy-specific phenotypes by utilising curated data in the IthaGenes database. IthaScore successfully reflects current knowledge for well-established disease modifiers, while it can be dynamically updated with emerging evidence. Protein–protein interaction (PPI) network analysis and functional enrichment analysis were employed to identify new potential disease modifiers and to evaluate the biological profiles of selected phenotypes. The most relevant gene ontology (GO) and pathway gene annotations for (a) haemoglobin (Hb) F levels/Hb F response to hydroxyurea included urea cycle, arginine metabolism and vascular endothelial growth factor receptor (VEGFR) signalling, (b) response to iron chelators included xenobiotic metabolism and glucuronidation, and (c) stroke included cytokine signalling and inflammatory reactions. Our findings demonstrate the capacity of IthaGenes, together with dynamic gene ranking, to expand knowledge on the genetic and molecular basis of phenotypic variation in haemoglobinopathies and to identify additional candidate genes to potentially inform and improve diagnosis, prognosis and therapeutic management.
format Online
Article
Text
id pubmed-6912721
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69127212020-01-02 Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies Stephanou, Coralea Tamana, Stella Minaidou, Anna Papasavva, Panayiota Kleanthous, Marina Kountouris, Petros J Clin Med Article Haemoglobinopathies are common monogenic disorders with diverse clinical manifestations, partly attributed to the influence of modifier genes. Recent years have seen enormous growth in the amount of genetic data, instigating the need for ranking methods to identify candidate genes with strong modifying effects. Here, we present the first evidence-based gene ranking metric (IthaScore) for haemoglobinopathy-specific phenotypes by utilising curated data in the IthaGenes database. IthaScore successfully reflects current knowledge for well-established disease modifiers, while it can be dynamically updated with emerging evidence. Protein–protein interaction (PPI) network analysis and functional enrichment analysis were employed to identify new potential disease modifiers and to evaluate the biological profiles of selected phenotypes. The most relevant gene ontology (GO) and pathway gene annotations for (a) haemoglobin (Hb) F levels/Hb F response to hydroxyurea included urea cycle, arginine metabolism and vascular endothelial growth factor receptor (VEGFR) signalling, (b) response to iron chelators included xenobiotic metabolism and glucuronidation, and (c) stroke included cytokine signalling and inflammatory reactions. Our findings demonstrate the capacity of IthaGenes, together with dynamic gene ranking, to expand knowledge on the genetic and molecular basis of phenotypic variation in haemoglobinopathies and to identify additional candidate genes to potentially inform and improve diagnosis, prognosis and therapeutic management. MDPI 2019-11-09 /pmc/articles/PMC6912721/ /pubmed/31717530 http://dx.doi.org/10.3390/jcm8111927 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Stephanou, Coralea
Tamana, Stella
Minaidou, Anna
Papasavva, Panayiota
Kleanthous, Marina
Kountouris, Petros
Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies
title Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies
title_full Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies
title_fullStr Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies
title_full_unstemmed Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies
title_short Genetic Modifiers at the Crossroads of Personalised Medicine for Haemoglobinopathies
title_sort genetic modifiers at the crossroads of personalised medicine for haemoglobinopathies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912721/
https://www.ncbi.nlm.nih.gov/pubmed/31717530
http://dx.doi.org/10.3390/jcm8111927
work_keys_str_mv AT stephanoucoralea geneticmodifiersatthecrossroadsofpersonalisedmedicineforhaemoglobinopathies
AT tamanastella geneticmodifiersatthecrossroadsofpersonalisedmedicineforhaemoglobinopathies
AT minaidouanna geneticmodifiersatthecrossroadsofpersonalisedmedicineforhaemoglobinopathies
AT papasavvapanayiota geneticmodifiersatthecrossroadsofpersonalisedmedicineforhaemoglobinopathies
AT kleanthousmarina geneticmodifiersatthecrossroadsofpersonalisedmedicineforhaemoglobinopathies
AT kountourispetros geneticmodifiersatthecrossroadsofpersonalisedmedicineforhaemoglobinopathies